A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Age ≥ 18 years * Incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior regimen * Evaluable or measurable disease per RECIST (in certain circumstances, prostate or ovarian cancer patients with non-measurable disease) Exclusion Criteria: * Inadequate hematologic or organ function * Anti-cancer therapy within 4 weeks prior to initiation of study treatment * Recent history of or current clinically significant gastrointestinal, cardiovascular or pulmonary disorders * Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytics, or a filter of the inferior vena cava * Active infection or autoimmune disease * Known human immunodeficiency virus (HIV) infection * Pregnancy or breast feeding